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Background
Identifying and / or designing molecules that can inhibit
HIV infection and be safe to the host cells is highly
desired.
Methods
HbAHP-25 was designed in silico against CD4 binding
domain of gp120 of HIV-1 by molecular docking using
Z dock and PROSA softwares. ELISA and SPR were
used to determine the binding ability of HbAHP-25 to
gp120. Anti-HIV activity of this peptide was checked by
two different assays, viz: a) On TZM bl cells, using luci-
ferase assay; b) On CEM-GFP cells and PBMCs using
p24 antigen assay. MTT assay, TER/microsphere assay
and Immunofluorescence were used to determine the
effect of HbAHP-25 on cell viability, epithelial mono-
layer integrity and permeability.
Results
Five peptides were designed, and one of the peptides,
HbAHP-25 , exhibits significant anti-HIV activity against
various strains of HIV-1, such as HIV-1 Ada, HIV-1
NL4-3, and HIV-1 IIIB. ELISA and SPR revealed a direct
interaction between HbAHP-25 and gp120, thereby inhi-
biting its interaction with CD4 receptor. The peptide
didn’t affect cell viability even at higher concentrations;
nor did it affect epithelial monolayer integrity or perme-
ability. HbAHP-25 also did not interfere with any tight
junction proteins such as ZO-1 and Clauddin-1, thus
maintaining cell integrity as well.
Conclusion
The peptide has potent anti-HIV activity, and can be
explored as a potential therapeutic /prophylactic/preventive
agent.
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